Clinical Trial Update: Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating Bortezomib combined with a PD-1 monoclonal antibody and the MFOLFIRINOX regimen for metastatic pancreatic cancer. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bortezomib (bortezomib)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• PD-1 monoclonal antibody

Snippet

Sponsor: Zhejiang University | Conditions: Pancreas Cancer | Phase 1, Phase 2 | Status: RECRUITING